EntryPoint Capital LLC Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

EntryPoint Capital LLC purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 24,816 shares of the company’s stock, valued at approximately $299,000. EntryPoint Capital LLC owned about 0.08% of Delcath Systems at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Delcath Systems by 3.0% during the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,298 shares during the period. Polar Asset Management Partners Inc. acquired a new stake in shares of Delcath Systems in the third quarter valued at approximately $1,594,000. Principal Financial Group Inc. boosted its stake in shares of Delcath Systems by 28.8% during the 4th quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock worth $1,387,000 after acquiring an additional 25,736 shares during the period. State Street Corp boosted its stake in shares of Delcath Systems by 12.4% during the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after acquiring an additional 9,400 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Delcath Systems during the 3rd quarter worth approximately $289,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Price Performance

Shares of NASDAQ DCTH opened at $13.40 on Friday. The firm has a market cap of $447.60 million, a price-to-earnings ratio of -9.93 and a beta of 0.82. The stock’s fifty day moving average price is $14.61 and its two-hundred day moving average price is $11.99. Delcath Systems, Inc. has a one year low of $4.26 and a one year high of $16.97.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The business had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter last year, the company posted ($0.48) earnings per share. On average, equities analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on DCTH shares. Craig Hallum raised their price target on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright increased their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.75.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.